Fehm & colleagues25, using a multivariate analysis, concluded that when serum Her-2/neu results were adjusted for tumour load with CA15-3, serum Her-2/neu remained an independent marker of tumour aggressiveness and reflected the biologic behaviour of the tumour. The gene discussed is ERBB2; the disease is neoplasm.